Melatonin Gummies Have a Label Accuracy Problem

The practice: selling a precise sleep dose in a candy-like format

The problem is not that every melatonin gummy is dangerously overdosed. The problem is that the category has shown poor dose reliability, and that matters more for gummies than for many other supplements. A gummy labeled 3 mg or 5 mg invites the user to treat the dose as exact. In the best-known U.S. analysis, that confidence was not justified: 25 melatonin gummy products were tested, and actual melatonin content ranged from 74% to 347% of the labeled amount. Only 3 products were within 10% of the label claim.1

That is a large miss for a hormone-active sleep supplement. It means a person taking a labeled 5 mg gummy could, in the worst tested case, be taking far more than expected. It also means a parent giving a child a partial dose could be making a decision from a label that does not reflect the product. The verdict is direct: melatonin gummies have a real overdosing and mislabeling problem, even if the available evidence does not prove that most individual users are being harmed.

What regulation does and does not do

In the United States, melatonin is generally sold as a dietary supplement. FDA says dietary supplements are regulated under a different framework than conventional foods and drugs, and manufacturers are responsible for ensuring their products are safe and properly labeled before marketing.² That means melatonin gummies do not go through FDA premarket approval for insomnia treatment the way prescription or over-the-counter drugs would.

There are rules. Dietary supplement manufacturers must follow current good manufacturing practice requirements under 21 CFR Part 111, which cover manufacturing, packaging, labeling, holding, quality control, and recordkeeping.³ FDA can inspect facilities, issue warning letters, and take enforcement action when products are adulterated or misbranded. But that is not the same as FDA testing every gummy bottle before it appears online or in a pharmacy.

The industry knows there is a credibility issue. In 2024, the Council for Responsible Nutrition adopted voluntary guidelines for melatonin-containing supplements and gummy supplements, including recommendations on formulation, labeling, packaging, and overage. The word voluntary is doing important work. These guidelines can push better actors toward tighter practices, but they do not bind every brand in the market.⁴

Third-party programs can help, but they are not universal. NSF lists certified dietary supplements and product-specific certifications, and consumers can search for melatonin products in that database.⁸ USP and NSF verification are quality signals, not proof that melatonin is right for a given person, but they are more meaningful than vague label language such as “lab tested” without a named certifier.

The public record: what testing found

The most cited case is the 2023 JAMA research letter that tested 25 gummy products listed in the NIH Dietary Supplement Label Database. The findings were not subtle. Twenty-two products were inaccurately labeled. One product had no detectable melatonin but contained 31.3 mg of cannabidiol, or CBD. Among products listing CBD, measured CBD ranged from 104% to 118% of the labeled amount.1

This was not a lawsuit against a single rogue brand and it was not a recall notice. It was a market sample, which makes the finding more useful and more limited. Useful, because it shows the problem can occur across products a shopper might actually buy. Limited, because 25 products cannot define the entire U.S. market, and formulas can change. The right conclusion is not “all melatonin gummies are dangerous.” The right conclusion is “the label cannot be assumed accurate unless quality is independently verified.”

The CBD finding also changes the risk calculation. A consumer buying melatonin may not expect CBD exposure at all, and a child ingesting gummies may be exposed to an unlabeled compound. That is not a theoretical labeling quibble. It is a failure of consumer control over what is being taken.

What harm evidence shows

The strongest harm data is pediatric exposure data, not adult overdose trials. CDC reported that pediatric melatonin ingestions reported to poison centers increased 530% from 2012 to 2021, reaching 260,435 total reports over that period. Most were unintentional, and the largest concern was young children finding and eating products at home.5

A later CDC report estimated about 11,000 emergency department visits from 2019 to 2022 for unsupervised melatonin ingestion among infants and young children. Many incidents involved flavored products, including gummies.⁶ This does not prove that label overages caused those visits. It does show why gummy format, household availability, and inaccurate dosing belong in the same safety conversation.

For adults, the harm case is less clean. Melatonin can cause next-day drowsiness, headache, dizziness, nausea, and can interact with some medicines or medical situations, according to NCCIH.⁷ But the evidence does not show a simple threshold where an extra few milligrams reliably becomes dangerous for every adult. The risk is unpredictability: users cannot adjust dose, timing, or side effects intelligently when the product does not contain what it says.

What to do as a consumer

If you use melatonin, treat gummies as the least precise option unless the product has credible third-party certification. Prefer a low-dose tablet or capsule from a brand that lists USP, NSF, or another specific independent verification program you can confirm. Avoid products that combine melatonin with CBD, herbs, or multiple sedatives unless a clinician has a reason for that combination.

Use the smallest dose that works, and do not assume “extra strength” is better. Melatonin is usually a timing tool for circadian rhythm and sleep onset, not a general sedative that improves with higher and higher doses. If you need it every night for more than a short stretch, the better question is why sleep is disrupted.

For homes with children, the practical rule is stricter: do not store melatonin gummies where a child can see or reach them. Child-resistant packaging helps, but it is not child-proof. Gummies look and taste like candy, and the surveillance data show that unsupervised pediatric ingestion is already common enough to send thousands of young children to emergency departments.⁶

The label problem is real. The fix is not panic. It is refusing to treat an uncertified gummy as a precise hormone dose.